Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome

Hematol Oncol. 2018 Feb;36(1):370-371. doi: 10.1002/hon.2464. Epub 2017 Jul 6.

Authors

Angela Fischer¹, Sara Bastian¹, Sergio Cogliatti², Ulrich Mey¹, Jenny Saub³, Urs Schanz³, Barbara Padberg⁴, Karin Hohloch^{1

5}

Affiliations

¹ Hämatologie und Onkologie, Kantonsspital Graubünden, Chur, Switzerland.
² Institut für Pathologie, Kantonsspital St. Gallen, St. Gallen, Switzerland.
³ Division of Hematology, University Spital Zuerich, Zuerich, Switzerland.
⁴ Division of Pathology, Kantonsspital Graubünden, Chur, Switzerland.
⁵ Hämatologie und Onkologie, Universität Goettingen, Goettingen, Germany.

PMID: 28681549
DOI: 10.1002/hon.2464

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Drug Resistance, Neoplasm / drug effects*
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology
Middle Aged
Piperidines
Pyrazoles / administration & dosage*
Pyrimidines / administration & dosage*
Syndrome

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine